Monomethylarsenic (MMA) bioavailability assessment in soil is a critical component of site-specific human health risk evaluation, providing scientifically defensible data on the fraction of organoarsenic contamination that is actually absorbed by the human body following incidental soil ingestion. This article presents a comprehensive technical overview of MMA sources, arsenic speciation analysis, in vitro bioaccessibility testing, and in vivo bioavailability validation methods, covering the complete evaluation workflow from sample preparation to regulatory application. By integrating chromatographic speciation techniques with physiologically based extraction tests, environmental professionals can refine exposure estimates, optimize remediation goals, and support compliance with soil environmental quality standards.
Technical Overview
Monomethylarsenic, occurring in soil predominantly as pentavalent monomethylarsonic acid (MMA(V), CH3AsO(OH)2) and its sodium salts (MSMA, DSMA), is an organoarsenic species that enters the soil environment through multiple pathways: the historical application of methylarsenic-based herbicides on cotton fields, golf courses, and orchards; microbial biomethylation of inorganic arsenic by soil bacteria and fungi under anaerobic conditions; industrial emissions from smelting and coal combustion; and land application of poultry litter containing roxarsone degradation products. Although regulatory frameworks have traditionally focused on inorganic arsenic species, MMA can constitute a substantial fraction of total arsenic in specific land-use settings, and its methylated chemistry confers distinct adsorption, mobility, and toxicological behaviors relative to arsenite and arsenate.
Bioavailability refers to the fraction of an ingested contaminant dose that is dissolved, absorbed across the gastrointestinal epithelium, and reaches systemic circulation. Bioaccessibility, the operationally defined companion parameter, represents the fraction that is released from the soil matrix into gastrointestinal fluids and is therefore available for absorption. Conventional risk assessments conservatively assume 100% oral bioavailability of soil-borne arsenic, which frequently overestimates actual exposure because arsenic species are often strongly sequestered by iron, aluminum, and manganese (hydr)oxides, clay minerals, and organic matter. Site-specific bioavailability assessment of monomethylarsenic replaces default assumptions with measured values, enabling more accurate hazard quantification, cost-optimized remediation targeting, and scientifically defensible regulatory decision-making in accordance with frameworks such as ISO 17924 and national risk-based soil screening methodologies.
Testing Samples
Agricultural and Paddy Soils
Cultivated soils from cotton, rice, orchard, and vegetable production systems where methylarsenic herbicides were historically applied or where methylation of geogenic arsenic is promoted by flooded, reducing conditions. Paddy soils in particular merit evaluation because alternate wetting-drying cycles drive dynamic arsenic speciation transitions among arsenite, arsenate, MMA, and dimethylarsenic species (DMA).
Contaminated Site Soils
Soils from former pesticide formulation and manufacturing facilities, wood preservation sites using chromated copper arsenate (CCA) adjacent to MMA-treated areas, chemical plant surroundings, and brownfield redevelopment parcels. These samples typically exhibit elevated total arsenic with heterogeneous speciation profiles requiring spatially dense sampling designs.
Turf and Golf Course Soils
Sandy root-zone soils from golf courses, sports turf, and sod farms with documented MSMA application histories. The coarse texture and acidic pH of these soils can enhance MMA mobility and bioaccessibility compared with fine-textured mineral soils.
Sediments and Dredged Materials
Riverine, lacustrine, and estuarine sediments impacted by arsenic-laden effluents, where microbial methylation under anoxic conditions generates methylated arsenic species. Dredged material destined for beneficial reuse requires bioavailability characterization prior to land application.
Mine Tailings and Smelter-Impacted Soils
Waste materials and surrounding soils from mining and metallurgical operations where arsenic trioxide and other process residues co-occur with methylated species generated by indigenous microbial communities.
Reference Materials and Quality Control Samples
Certified reference soils for total arsenic, laboratory control samples, matrix spikes, duplicates, and procedural blanks to validate the full analytical sequence from extraction through instrumental quantification.
Testing Items
The testing portfolio for a monomethylarsenic bioavailability evaluation integrates concentration-based, speciation-based, and physiologically based parameters:
- Total arsenic concentration following aqua regia or four-acid total digestion, referenced against ISO 11885, EPA Method 3050B/3051A, or equivalent national protocols.
- Complete arsenic speciation profile: arsenite As(III), arsenate As(V), monomethylarsonic acid MMA(V), dimethylarsinic acid DMA(V), and trimethylarsine oxide TMAO, with optional determination of thiolated species in sulfidic soils.
- Gastric-phase and gastrointestinal-phase bioaccessible arsenic concentrations, reported as absolute values and as percentages of total arsenic.
- Species-specific bioaccessibility of MMA, distinguishing the bioaccessible fraction of methylated arsenic from that of inorganic species within the same extract.
- Relative bioavailability (RBA) values derived by benchmarking soil responses against sodium arsenate or MMA reference doses in paired in vitro or in vivo assays.
- Matrix characterization parameters influencing arsenic binding: pH, redox potential (Eh), soil organic carbon, cation exchange capacity, amorphous and crystalline Fe/Al/Mn (hydr)oxide content, phosphate concentration, and particle-size distribution.
- Leaching mobility indicators, including TCLP-type extraction results, to differentiate ingestion-pathway hazard from groundwater migration potential.
Testing Methods
Sample Preparation and Preservation
Field-moist samples are transported chilled to minimize microbial transformation of arsenic species. Upon receipt, samples are either air-dried at room temperature or freeze-dried under vacuum, gently disaggregated, homogenized, and sieved to less than 250 µm for oral bioaccessibility testing in accordance with ISO 17924 guidance, or to 2 mm for general soil characterization. Speciation-critical subsamples are stored frozen and analyzed under expedited timeframes to limit interconversion between oxidation states and methylation states.
Total Arsenic Determination
Total arsenic is quantified following microwave-assisted digestion using hydrofluoric acid-inclusive total digestion or aqua regia partial digestion depending on data objectives. Instrumental measurement employs inductively coupled plasma mass spectrometry (ICP-MS) per ISO 17294-2 and EPA Method 6020B, inductively coupled plasma optical emission spectrometry (ICP-OES) for high-concentration matrices, or portable X-ray fluorescence (EPA Method 6200) as a field-screening tool. Collision-reaction cell technology and chloride interference correction ensure accurate arsenic quantification at sub-mg/kg detection limits.
Arsenic Speciation by Chromatographic Coupling
Species separation is performed using high-performance liquid chromatography (HPLC) with anion-exchange columns and phosphate-based mobile phases, followed by detection via ICP-MS or hydride generation atomic fluorescence spectrometry (HG-AFS) consistent with methods such as HJ 702 and EPA speciation protocols. Soil extraction employs mild phosphate, ammonium oxalate, or phosphoric acid extractants selected to achieve quantitative recovery while preserving species integrity. Method validation includes speciated certified reference materials, spike recoveries of 75–125%, retention-time confirmation, and mass-balance reconciliation against total arsenic within 80–120%.
In Vitro Bioaccessibility Testing
Physiologically based extraction tests simulate human gastrointestinal chemistry to estimate bioaccessibility. Recognized protocols include the Unified Bioaccessibility Method (UBM) developed by the Bioaccessibility Research Group of Europe, the Solubility Bioaccessibility Research Consortium method (SBRC/SBET) validated by EPA Method 1340 for lead and arsenic in soil, the in vitro gastrointestinal method (IVG), the physiologically based extraction test (PBET), the German DIN 19738 method, and the RIVM in vitro digestion model. Testing encompasses a gastric phase (pH 1.2–1.5, pepsin, glycine buffer) and, where methodologically appropriate, a small-intestinal phase (pH 5.5–7.0, bile and pancreatin). Extracts are centrifuged, filtered, and analyzed by ICP-MS for total bioaccessible arsenic, with parallel HPLC-ICP-MS analysis to quantify bioaccessible MMA specifically.
In Vivo Bioavailability Validation
Where regulatory programs require definitive absorption data, in vivo assays using juvenile swine, mice, or rabbits are conducted under institutional animal care approval. Test animals receive soil-dosed diets alongside sodium arsenate or MMA reference-dose controls, and absolute/relative bioavailability is computed from urinary arsenic excretion, blood arsenic kinetics, or tissue burdens, with speciation of urinary metabolites distinguishing absorbed MMA and its biotransformation products. In vivo results are used to calibrate and validate the correlation between in vitro bioaccessibility and true bioavailability for a given soil type and contaminant scenario.
Supporting Geochemical Characterization
Complementary assessments include sequential chemical extraction following the Wenzel or BCR schemes to allocate arsenic among exchangeable, specifically adsorbed, amorphous oxide-bound, crystalline oxide-bound, and residual fractions; diffusive gradients in thin films (DGT) to measure labile arsenic flux as a surrogate for phytoavailable and potentially bioavailable pools; and measurements of reactive iron oxide content via citrate-bicarbonate-dithionite and oxalate extractions to interpret sequestration mechanisms controlling bioaccessibility.
Applications
Monomethylarsenic bioavailability data directly support human health risk assessment under frameworks aligned with national soil environmental quality risk control standards, replacing generic exposure assumptions with site-specific relative bioavailability factors in the incidental soil ingestion pathway, which is typically the dominant route for children. The resulting refined hazard quotients and carcinogenic risk estimates enable derivation of site-specific remediation goals that can substantially reduce remediation footprints and project costs while maintaining protectiveness.
- Site-specific risk assessment and derivation of remediation target concentrations for brownfield and industrial land redevelopment.
- Performance verification of stabilization and solidification remedies, where amendments such as iron oxides, biochar, and clays are evaluated by their capacity to reduce MMA bioaccessibility rather than merely total concentration.
- Regulatory compliance demonstrations and closure submissions to environmental authorities, supported by ISO 17025-accredited laboratory data packages.
- Agricultural food-safety evaluations linking soil MMA bioavailability to crop uptake in paddy systems and vegetable production.
- Environmental forensics to distinguish herbicide-derived MMA signatures from geogenic and industrial arsenic sources in litigation and allocation disputes.
- Scientific research into arsenic biogeochemical cycling, microbial methylation pathways, and climate-driven redox effects on species transformation.
- Priority ranking of contaminated parcels within portfolio management programs, directing intervention resources toward soils with the highest bioavailable fractions.
FAQ
What is the difference between bioavailability and bioaccessibility? Bioavailability is the fraction of an ingested dose that actually reaches systemic circulation and becomes toxicologically active, typically measured in animal models. Bioaccessibility is the fraction that dissolves in simulated gastrointestinal fluids and is therefore available for absorption, measured in vitro. Regulators increasingly accept validated in vitro bioaccessibility data as a surrogate when a documented correlation with in vivo bioavailability exists for the relevant contaminant and soil matrix.
Is monomethylarsenic more toxic than inorganic arsenic? Pentavalent MMA(V), the form expected in aerobic soils, is generally considered less acutely toxic than inorganic arsenite and arsenate. However, trivalent MMA(III), a microbial metabolite that can transiently occur in reducing environments, exhibits high cytotoxicity. This species-dependent toxicity is precisely why chromatographic speciation, rather than total arsenic alone, is essential for defensible risk characterization.
How is relative bioavailability calculated? Relative bioavailability expresses the bioavailable fraction in soil relative to the bioavailable fraction of a reference material, typically sodium arsenate dissolved in water or diet. In in vivo studies it is calculated from the ratio of urinary arsenic excretion following soil dosing to that following reference dosing; in vitro it is the ratio of bioaccessible arsenic in the gastrointestinal extract to the dissolved arsenic from the reference compound.
Which soil properties most strongly influence MMA bioaccessibility? Amorphous iron and aluminum (hydr)oxide content is the dominant sequestration control, followed by soil organic matter, pH, phosphate competition for sorption sites, and clay mineralogy. Elevated phosphate can displace MMA from oxide surfaces and increase bioaccessibility, whereas iron-rich, near-neutral soils typically exhibit the lowest bioaccessible fractions.
Are in vitro bioaccessibility results accepted by regulators? Yes. EPA Method 1340 and the UBM method have undergone multi-laboratory validation for arsenic in soil, and ISO 17924 provides international guidance on the selection and application of physiologically based extraction methods. Acceptance typically requires use of a validated protocol, demonstration of method-specific absorbance of quality controls, and application of established regression models converting bioaccessibility to relative bioavailability.
What sample quantity and turnaround time should be expected? A typical evaluation requires 200–500 g of soil per sampling location to accommodate total arsenic, speciation, bioaccessibility, and characterization testing with sufficient volume for confirmatory analyses. Standard turnaround is 15–30 working days, with species-stability constraints favoring expedited handling of frozen subsamples for chromatographic speciation.